Literature DB >> 8940255

FMS (CSF-1 receptor) prolongs cell cycle and promotes retinoic acid-induced hypophosphorylation of retinoblastoma protein, G1 arrest, and cell differentiation.

A Yen1, R Sturgill, S Varvayanis, R Chern.   

Abstract

The effect of the CSF-1 receptor, cFMS, on the phosphorylation of the retinoblastoma (RB) tumor suppressor protein and on the cell cycle and cell differentiation was analyzed in a cultured promyelocytic leukemia cell capable of induced myelomonocytic differentiation. A series of cFMS-transfected HL-60 sublines with progressively higher cell surface FMS expression was derived by flow cytometric cell sorting. Overexpression of FMS increased the duration of the cell cycle, prolonging all cell cycle phases especially S phase, which doubled. The increased cell cycle generation times occurred without any detectable changes in RB expression level or phosphorylation. For retinoic acid (RA)-induced myeloid differentiation, progressive overexpression of FMS caused a greater fraction of cells to differentiate and G1/0 arrest compared to wild-type cells after the same number of cell cycle generation times. FMS overexpression also progressively increased the relative amount of dephosphorylated RB protein induced, while reducing the total amount of RB protein. The inducer-originated and FMS-driven changes in RB hypophosphorylation were not effected through changes in p21/WAF1/CIP1 in this p53-negative cell. Similar effects on differentiation and G0 arrest occurred with 1,25-dihydroxy vitamin D3 (D3)-induced monocytic differentiation. FMS did not significantly affect myeloid differentiation induced by DMSO, which does not target steroid-thyroid hormone receptors like RA and D3. While differentiation is typically associated with hypophosphorylated RB in all these cases, the kinetics indicate that the FMS-induced changes in cell cycle and cell differentiation do not depend in a direct causal fashion on the interconversion between hyperphosphorylated and hypophosphorylated RB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940255     DOI: 10.1006/excr.1996.0349

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: analysis by disease type and comparison with normal human hematopoietic cells.

Authors:  S Hagiwara; M Yagisawa; K Saeki; S Iki; A Urabe; T Mimura; A Miwa; A Togawa; M Higashihara; F Takaku; A Yuo
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

2.  Retinoic acid increases amount of phosphorylated RAF; ectopic expression of cFMS reveals that retinoic acid-induced differentiation is more strongly dependent on ERK2 signaling than induced GO arrest is.

Authors:  A Yen; S Varvayanis
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-04       Impact factor: 2.416

3.  Polyomavirus small t antigen prevents retinoic acid-induced retinoblastoma protein hypophosphorylation and redirects retinoic acid-induced G0 arrest and differentiation to apoptosis.

Authors:  A Yen; L Placanica; S Bloom; S Varvayanis
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Retinoic acid induces nuclear accumulation of Raf1 during differentiation of HL-60 cells.

Authors:  James Smith; Rodica P Bunaciu; Gudrun Reiterer; David Coder; Thaddeus George; Michael Asaly; Andrew Yen
Journal:  Exp Cell Res       Date:  2009-03-17       Impact factor: 3.905

5.  Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene.

Authors:  Hyun Jin Kwun; Kyung Lib Jang
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

6.  Human myeloblastic leukemia cells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation.

Authors:  M Ariel Kauss; Gudrun Reiterer; Rodica P Bunaciu; Andrew Yen
Journal:  Exp Cell Res       Date:  2008-07-26       Impact factor: 3.905

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.